2.

Clinical parameters from clinical trials using HDi as single agents

Drug	HDACs targeted	Phase	Method of delivery	Dosage range	Adverse reactions
Panobinostat (LBH589)	Class I, II	I	Oral	20 mg/m2	Grade 3 diarrhoea
MGCD0103	Class I	I	Oral	60 mg/m2	Fatigue, nausea, vomiting and diarrhoea
Vorinostat	Class I, II	FDA approved	Oral	200–600 mg/m2	Fatigue, dehydration, nausea and vomiting
MS-275	Class I	II	Oral	2–6 mg/m2	Hypophosphatemia, hyponatremia and hypoalbuminemia
VPA	Class I	II	Oral	60 mg/kg/day	Grade 3, 4 neurocognitive impairment
Phenylbutyrate	Class I,II	I/II	Oral and intravenous (i.v.) infusion	60–360 mg/kg/day	Reversible neurocortical toxicity characterized by somnolence and confusion, short-term memory loss, sedation, confusion, nausea and vomiting
Pivanex (AN-9)		II	i.v. infusion	2.34 g/m2/day	Nausea, vomiting, hyperglycaemia, fatigue, diarrhoea and visual complaints
CI-994	Class I	I/II	Oral	4–6 mg/m2/day	Thrombocytopenia, fatigue, nausea, vomiting, diarrhoea, constipation and mucositis
Belinostat (PXD101)	Class I, II	I/II	i.v. infusion	1000 mg/m2/day	Nausea, vomiting, fatigue and flushing atrial fibrillation
Two cases of grade 4 renal failure
Romidepsin	Class I	I/II	i.v. infusion	10–26 mg/m2	Reversible cardiac dysrhythmias and non-specific ECG abnormalities thromocytopenia